Aaron Elliott, Ph.D., is Chief Executive Officer of Freenome, where he leads strategy and operational execution for blood-based cancer detection. He previously served as CEO of REALM IDx and led Ambry Genetics, with experience spanning early cancer detection, multiomics, hereditary cancer testing, diagnostics, and commercial growth.
Aaron Elliott, Ph.D., is Chief Executive Officer of Freenome, where he leads strategy and operational execution for blood-based cancer detection. He previously served as CEO of REALM IDx and led Ambry Genetics, with experience spanning early cancer detection, multiomics, hereditary cancer testing, diagnostics, and commercial growth.
Career
Aaron Elliott studied at Thomas Jefferson University, Sidney Kimmel Cancer Center (Ph.D. training in genetics), The Johns Hopkins University School of Medicine (Ph.D. training in genetics), and Franklin & Marshall College (Bachelor of Science in Biology).
Chief Executive Officer at Freenome until Present